Clinical trials: Methamphetamine
Methamphetamine Dependence
An Study of Paliperidone Extended-Release Tablets in the Treatment of Methamphetamine Dependence
Methamphetamine substance use is common worldwide. No approved pharmacologic treatments for methamphetamine dependence exist. paliperidone are Second generation antipsychotics，and have effects of blocking dopamine2(D2) and…
- Trial name
- NCT01825928
- Testing
- Paliperidone
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Wei Hao
Amphetamine Use Disorders
Closed-loop tTIS Targeted of the Nac as an Intervention for MUD Patients
Closed-loop transcranial temporal interference stimulation (tTIS) targeting the nucleus accumbens may modulate abnormal neural responses to drug-related cues in individuals with methamphetamine use disorder (MUD), thereby…
- Trial name
- NCT07802223
- Testing
- Temporal Interference Stimulation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Mental Health Center
Stimulant Overdose, Overdose Accidental
Leveraging Psychological Autopsies to Accelerate Research Into Stimulant Overdose Mortality
In the LASSO study, the investigators will identify 100 stimulant overdose decedents (divided among stimulant-only, and stimulant with fentanyl), conduct informant interviews (including scales and qualitative data), and gather…
- Conditions
- Stimulant Overdose, Overdose Accidental, Overdose Cocaine, Overdose Methamphetamine
- Trial name
- LASSO (NCT06076564)
- Where
- United States
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- San Francisco Department of Public Health
Opioid-Related Disorders, Stimulant-Related Disorder
Preventing Parental Opioid and/or Methamphetamine Addiction Within DHS-Involved Families: PRE-FAIR
Young parents aged 16 to 30, involved in the DHS system for child welfare or self-sufficiency needs are at risk for opioid use disorder and/or methamphetamine use disorder (OUD; MUD).
- Conditions
- Opioid-Related Disorders, Stimulant-Related Disorder, Child Neglect, Mental Health Impairment
- Trial name
- PRE-FAIR (NCT05380440)
- Testing
- Prevention Adaptation of Families Actively Improving Relationships (PRE-FAIR), Standard Case Management and Referral
- Where
- United States
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- Chestnut Health Systems
Drug Addiction
Drug Effects on Preference and Reward
Classical conditioning is widely used to study motivational properties of addictive drugs in animals, but has rarely been used in humans.
- Trial name
- NCT01722006
- Testing
- Pairing condition
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Methamphetamine Dependence
Open-Label Disulfiram for Methamphetamine Dependence
This 8 week, open-label pilot clinical trial will examine the safety and tolerability of disulfiram at 250 mg/day in up to fifteen methamphetamine dependent individuals.
- Trial name
- NCT00731133
- Testing
- Disulfiram
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Arkansas
Stimulant Use Disorder, Cocaine Use Disorder
LDART for Stimulant Use Disorder
The goal of this study is to evaluate the feasibility, acceptability, and preliminary efficacy of a digital intervention called LDART in adults with stimulant use disorder.
- Conditions
- Stimulant Use Disorder, Cocaine Use Disorder, Methamphetamine Use Disorder
- Trial name
- LDART (NCT07221396)
- Testing
- LDART, Psychoeducational booklet
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Yale University
Methamphetamine Dependence
Risk and Protective Factors for Rural Methamphetamine Dependence
The primary goal of this study is to identify factors which may put a person that has used methamphetamine at greater risk for mental and physical health problems and social problems and factors that may lessen the risk for these…
- Trial name
- NCT00882037
- Where
- 2 sites in United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Amphetamine-Related Disorders
Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM)
Extended-release naltrexone (XR-NTX, VIVITROL) is an FDA-approved medication with efficacy in treating alcohol dependence and prevention of relapse to opioid dependence.
- Trial name
- TREX (NCT01449565)
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- San Francisco Department of Public Health
Amphetamine-Related Disorders
Bupropion for the Treatment of Methamphetamine Dependence - 1
The purpose of this study is to assess the efficacy and safety of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence
- Trial name
- NCT00069251
- Testing
- Bupropion
- Where
- 5 sites in United States
- Volunteers
- 150 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Cognitive Dysfunction, Stimulant Use
Change in Cognitive Function in Stimulant Users
In Hong Kong, methamphetamine use is common and cocaine use has increased steadily over the past few years. While the use of ketamine decreased from 35.8% in 2015 to 13.9% in 2017, methamphetamine and cocaine have become the most…
- Conditions
- Cognitive Dysfunction, Stimulant Use, Methamphetamine Abuse, Cocaine Use
- Trial name
- SToP-S_CogFx (NCT04061941)
- Testing
- Cognitive Assessment
- Where
- Hong Kong
- Volunteers
- 93 people
- Sponsor
- The University of Hong Kong
Methamphetamine Dependence
Efficacy and Safety of CDP-choline in Patients With Methamphetamine Dependence
The purpose of the study is to determine if cytidine 5'diphosphocholine (CDP-choline, a naturally occurring chemical in your body) has efficacy in reducing the methamphetamine craving of the subjects with methamphetamine…
- Trial name
- NCT01007539
- Testing
- CDP-choline
- Where
- 2 sites in South Korea
- Volunteers
- 31 people
- Sponsor
- Seoul National University Hospital
Dopamine D2/3 Receptor Availability, Cognitive Function
Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users
While deficits in dopamine D2-type receptor availability have been linked to substance use disorders, higher availability associates with better behavioral treatment outcomes for stimulant dependence and resilience to addiction.
- Conditions
- Dopamine D2/3 Receptor Availability, Cognitive Function, Methamphetamine Abuse
- Trial name
- NCT03059563
- Testing
- Varenicline
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of California, Los Angeles
Methamphetamine-dependence
Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users
Addiction to methamphetamine is a serious health problem in the United States. Right now, there are no medications that a doctor can give someone to help them stop using methamphetamine.
- Trial name
- Ibudilast (NCT03341078)
- Testing
- Ibudilast
- Where
- United States
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Methamphetamine Abuse, Newborn Complication | Patient | Neonatalology
Cardiovascular Effects of Prenatal Methamphetamine Exposure
Methamphetamine (MA) is one of the commonly used drugs during pregnancy. Cardiovascular effects of MA include elevated blood pressure, acute vasospasm, atherosclerotic disease, structural and electrical remodeling of cardiac…
- Trial name
- NCT04616625
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Methamphetamine Abuse
Safety Study of Ch-mAb7F9 for Methamphetamine Abuse
The primary objective is to determine the safety and tolerability of single, ascending intravenous doses of ch-mAb7F9 in healthy subjects via physical examinations and adverse event, vital sign, electrocardiogram (ECG), and…
- Trial name
- NCT01603147
- Testing
- normal saline, ch-mAb7f9
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- InterveXion Therapeutics, LLC
Methamphetamine-dependence
Glutide for Ending Methamphetamine
GEM is a two-phase study to evaluate the use of semaglutide (Wegovy) for the treatment of methamphetamine use disorder (MeUD). The first phase is a pilot study, which will be an open-label, single-arm pilot study of 25…
- Trial name
- GEM (NCT07204249)
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- San Francisco Department of Public Health
Methamphetamine Dependence
Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence
This study is to assess the efficacy of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence who report using methamphetamine 29 or less days during the 30 days prior to the start of signing…
- Trial name
- NCT00687713
- Testing
- Bupropion
- Where
- 12 sites in United States
- Volunteers
- 200 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Methamphetamine Abuse, Opioid-use Disorder
Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics
The investigators propose to develop and evaluate optimal combinations of evidence-based interventions to improve HIV outcomes and reduce methamphetamine use (hereafter: meth use) among people with opioid use disorder who are in…
- Conditions
- Methamphetamine Abuse, Opioid-use Disorder, HIV Seropositivity
- Trial name
- STAR-OM (NCT04706624)
- Testing
- Contingency management (12 weeks), Contingency management (6 weeks), SMS reminders
- Where
- 4 sites in Vietnam
- Volunteers
- 667 people
- Sponsor
- Hanoi Medical University
Methamphetamine Abuse, HIV
Theory-based Text Messaging to Reduce Methamphetamine Use and HIV Risks Among MSM
Participants receive culturally relevant and specifically tailored text messages based on the behavioral change theoretical constructs of Social Support Theory, Health Belief Model, and Social Cognitive Theory.
- Trial name
- NCT02008526
- Testing
- Text Messages Transmitted by Peer Health Educators (TXT-PHE), Text Messages Transmitted by Automation (TXT-Auto)
- Where
- United States
- Volunteers
- 286 people
- Sponsor
- Friends Research Institute, Inc.